TY - JOUR
T1 - MM-361 The Prognostic Role and Utility of Highly Sensitive Minimal Residual Disease Assay in Multiple Myeloma
T2 - Is There Really a Difference?
AU - Fonseca, Rodrigo
AU - Wiedmeier, Julia E.
AU - Arribas, Mariano
AU - Fonseca, Rafael
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10
Y1 - 2022/10
N2 - Context: The role of higher-sensitivity minimal residual disease (MRD) assays in predicting survival outcomes and guiding treatment decisions remains to be validated in patients with multiple myeloma (MM). Objective: To determine the predictive and prognostic role of high-sensitivity next-generation sequencing (NGS) MRD assays in patients with MM undergoing autologous stem cell transplant (ASCT). Design: We performed a retrospective analysis on a cohort of patients diagnosed with MM between 2015 and 2020. All patients underwent front-line ASCT and were evaluated with an NGS MRD assay with a sensitivity of 10–6 at day 100 post-ASCT. Main Outcome Measures: Given the retrospective nature of the study, we used the time to next treatment (TTNT) as a surrogate marker for progression-free survival. Overall survival (OS) was included as a secondary analysis. Results: A total of 186 patients were included in the analysis. With a mean follow-up time after ASCT of 30.2 months, patients who achieved MRD negativity at 10–6 had longer TTNT than patients achieving negativity at 10–5 or lower thresholds (HR: 0.289, 95% CI: 0.110–0.758, p=0.0116). On multivariable analysis, adjusting for the R-ISS stage, IMWG response category, and cytogenetic risk status, MRD negativity with a sensitivity of 10–6 was the strongest prognostic factor for longer TTNT. MRD alone did not predict OS, which may be associated with the relatively limited follow-up time. Additionally, patients who achieved sustained MRD negativity, defined as negative MRD confirmed after 1 year, had significantly longer TTNT in both the univariate (HR: 0.07, 95% CI: 0.01–0.63, p=0.0175) and multivariable (HR: 0.0109, CI: 0.0003–0.4199, p=0.0153) models. At cutoff, of the 23 patients with sustained MRD negativity, 13 (57%) had been off therapy for a mean duration of 14 months after the second measurement with no documented progressions or deaths. Conclusions: Overall, MRD negativity at a sensitivity of 10–6 was associated with a longer TTNT, regardless of induction therapy regimen or baseline characteristics. Higher-sensitivity MRD assays can help identify a subset of patients with very low disease burden who have a decreased risk of progression and could help guide therapy-related decisions, including treatment discontinuation.
AB - Context: The role of higher-sensitivity minimal residual disease (MRD) assays in predicting survival outcomes and guiding treatment decisions remains to be validated in patients with multiple myeloma (MM). Objective: To determine the predictive and prognostic role of high-sensitivity next-generation sequencing (NGS) MRD assays in patients with MM undergoing autologous stem cell transplant (ASCT). Design: We performed a retrospective analysis on a cohort of patients diagnosed with MM between 2015 and 2020. All patients underwent front-line ASCT and were evaluated with an NGS MRD assay with a sensitivity of 10–6 at day 100 post-ASCT. Main Outcome Measures: Given the retrospective nature of the study, we used the time to next treatment (TTNT) as a surrogate marker for progression-free survival. Overall survival (OS) was included as a secondary analysis. Results: A total of 186 patients were included in the analysis. With a mean follow-up time after ASCT of 30.2 months, patients who achieved MRD negativity at 10–6 had longer TTNT than patients achieving negativity at 10–5 or lower thresholds (HR: 0.289, 95% CI: 0.110–0.758, p=0.0116). On multivariable analysis, adjusting for the R-ISS stage, IMWG response category, and cytogenetic risk status, MRD negativity with a sensitivity of 10–6 was the strongest prognostic factor for longer TTNT. MRD alone did not predict OS, which may be associated with the relatively limited follow-up time. Additionally, patients who achieved sustained MRD negativity, defined as negative MRD confirmed after 1 year, had significantly longer TTNT in both the univariate (HR: 0.07, 95% CI: 0.01–0.63, p=0.0175) and multivariable (HR: 0.0109, CI: 0.0003–0.4199, p=0.0153) models. At cutoff, of the 23 patients with sustained MRD negativity, 13 (57%) had been off therapy for a mean duration of 14 months after the second measurement with no documented progressions or deaths. Conclusions: Overall, MRD negativity at a sensitivity of 10–6 was associated with a longer TTNT, regardless of induction therapy regimen or baseline characteristics. Higher-sensitivity MRD assays can help identify a subset of patients with very low disease burden who have a decreased risk of progression and could help guide therapy-related decisions, including treatment discontinuation.
KW - MM
KW - minimal residual disease
KW - multiple myeloma
KW - next-generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85138137166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138137166&partnerID=8YFLogxK
U2 - 10.1016/S2152-2650(22)01618-4
DO - 10.1016/S2152-2650(22)01618-4
M3 - Article
C2 - 36164169
AN - SCOPUS:85138137166
SN - 2152-2650
VL - 22
SP - S420
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
ER -